A pilot study involving 10 HCC patients with vascular infiltration showed that after treatment with anti-PD-1 antibody combined with VEGFR-targeted TKI, 7 patients achieved PR, 3 patients achieved CR, and all 10 patients underwent surgery with a recurrence-free survival rate of 75% within 12 months [22]. The gene discussed is KDR; the disease is hepatocellular carcinoma.